Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
AssigneeUniversity of Louisville Research Foundation, Inc.
InventorsMohammad Tariq Malik, Martin G. O'Toole, Paula J. Bates
Life of this patent
Estimating the term…
Abstract
A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.
Claims25
A composition, comprising an anti-nucleolin agent and gadolinium conjugated to nanoparticles.
(canceled)
5-8. (canceled)
15-17. (canceled)
A method of treating cancer, comprising administering an effective amount of a pharmaceutical composition comprising an anti-nucleolin agent conjugated to nanoparticles, to a patient in need thereof, followed by radiation therapy.
(canceled)
22-25. (canceled)
A method of imaging cancer by MRI and/or X-ray imaging techniques in vivo, comprising:
- administering a composition comprising an anti-nucleolin agent and gadolinium conjugated to nanoparticles to a subject;
- and
- forming an image of the imaging agent present in the subject by MRI and/or an X-ray imaging technique.
Dependencies are inferred from the claim text.